The U.S. Food and Drug Administration (FDA) has approved Libtayo (cemiplimab-rwlc), making it the first immunotherapy for people with advanced basal cell carcinoma (BCC) — the most common form of skin cancer — who previously received or were ineligible for treatment with a hedgehog pathway inhibitor. Based on the results of an ongoing Phase 2 trial, called Study 1620 (NCT03132636), the therapy was granted full approval for patients with locally advanced disease — cancer that…
You must be logged in to read/download the full post.
The post FDA Approves Libtayo, 1st Immunotherapy for Advanced Basal Cell Carcinoma appeared first on BioNewsFeeds.